HomeCompareGNGBY vs PFE

GNGBY vs PFE: Dividend Comparison 2026

GNGBY yields 2.32% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNGBY wins by $124.05M in total portfolio value
10 years
GNGBY
GNGBY
● Live price
2.32%
Share price
$20.57
Annual div
$0.48
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$124.10M
Annual income
$114,616,754.52
Full GNGBY calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — GNGBY vs PFE

📍 GNGBY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNGBYPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNGBY + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNGBY pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNGBY
Annual income on $10K today (after 15% tax)
$197.38/yr
After 10yr DRIP, annual income (after tax)
$97,424,241.34/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, GNGBY beats the other by $97,401,921.44/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNGBY + PFE for your $10,000?

GNGBY: 50%PFE: 50%
100% PFE50/50100% GNGBY
Portfolio after 10yr
$62.07M
Annual income
$57,321,506.62/yr
Blended yield
92.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

GNGBY
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
2.6
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNGBY buys
0
PFE buys
0
No recent congressional trades found for GNGBY or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNGBYPFE
Forward yield2.32%6.13%
Annual dividend / share$0.48$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$124.10M$49.6K
Annual income after 10y$114,616,754.52$26,258.71
Total dividends collected$123.36M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldHold

Year-by-year: GNGBY vs PFE ($10,000, DRIP)

YearGNGBY PortfolioGNGBY Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,164$464.43$9,153$693.39+$2.0KGNGBY
2$12,915$969.18$8,593$849.25+$4.3KGNGBY
3$15,915$2,095.61$8,336$1,066.78+$7.6KGNGBY
4$21,856$4,826.80$8,437$1,384.80+$13.4KGNGBY
5$35,775$12,389.91$9,013$1,875.40+$26.8KGNGBY
6$76,188$37,908.46$10,306$2,680.72+$65.9KGNGBY
7$232,420$150,898.52$12,820$4,101.38+$219.6KGNGBY
8$1,109,122$860,432.66$17,673$6,826.70+$1.09MGNGBY
9$8,861,597$7,674,836.93$27,543$12,591.86+$8.83MGNGBY
10$124,098,664$114,616,754.52$49,560$26,258.71+$124.05MGNGBY

GNGBY vs PFE: Complete Analysis 2026

GNGBYStock

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers sterile transfer systems, closure processing systems, washers, isolators, sterilizers, logistic automation solutions, bioreactors, bioprocess control systems, bioprocess software, biobundles, bioprocess analytics, and perfusion systems; practice-oriented monitoring systems and disposables, anesthesia machines, beating heart stabilizers and positioners, axius blower mister and coronary shunts, proximal seal systems, ceiling supply units, connected solutions, cleaning and disinfection products, packaging and sealing solutions, monitors and indicators, and SteriTec products. The company also provides thoracic catheters, dry seal chest drain, mobile dry seal drain, dry and wet suction water seal chest drain, and chest drain valves; transitional accessories; endoscope reprocessing; endoscopic vessel harvesting systems; endovascular products; extracorporeal life support or extracorporeal membrane oxygenation products; inspection and packing products; intra-aortic balloon counter pulsation therapies; mechanical ventilation products; medical furniture; modular room systems; operating lights and tables; OR integration and management; patient flow management; patient transport; sterile supply management; sterilization; surgical assist systems; surgical perfusion; transport & storage; trays & baskets; and vascular and cardiothoracic surgery solutions. It offers its products through a network of proprietary sales companies, as well as through agents and distributors in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Getinge AB (publ) was founded in 1904 and is headquartered in Gothenburg, Sweden.

Full GNGBY Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this GNGBY vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNGBY vs SCHDGNGBY vs JEPIGNGBY vs OGNGBY vs KOGNGBY vs MAINGNGBY vs JNJGNGBY vs MRKGNGBY vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.